公开(公告)号：EP0341291A4

公开(公告)日：1990-07-03

申请号：EP89900112

申请日：1988-11-08

Applicant: BAXTER INT

Inventor： BACEHOWSKI DAVID V ,  MIRIPOL JEFFREY E ,  NEEDHAM THOMAS E ,  KARTINOS NICHOLAS J

IPC: A61K9/22 ,  A61M1/02 ,  A61M1/36

CPC classification number: A61M1/3672 ,  A61M1/3673

Abstract: As one administers blood through a conduit (10) into a container (12), the blood is passed in the conduit across the supply of beneficial agent (18), such as anticoagulant, to cause a controlled amount of beneficial agent to enter the passing blood in a manner that is substantially uniform overtime. The beneficial agent (18) is typically in dry form until it enters into contact with the blood. Accordingly, no substantial portion of the blood is exposed to a significantly higher concentration of the beneficial agent than other portions of the blood.

Abstract translation: 当通过导管（10）将血液施用到容器（12）中时，血液在管道中通过有益剂（18）的供应，例如抗凝血剂，以引起受控量的有益剂进入通过 血液的加班时间基本一致。 有益剂（18）通常是干燥形式，直到其与血液接触。 因此，与血液的其他部分相比，没有相当一部分血液暴露于有益剂量的明显更高的浓度。

公开(公告)号：CA1339088C

公开(公告)日：1997-07-29

申请号：CA582994

申请日：1988-11-14

Applicant: BAXTER INT

Inventor： BACEHOWSKI DAVID V ,  MIRIPOL JEFFREY E ,  NEEDHAM THOMAS E ,  KARTINOS NICHOLAS J

IPC: A61K9/22 ,  A61M1/02 ,  A61M1/36

Abstract: As one administers blood through a conduit into a container, the blood is passed in the conduit across the supply of beneficial agent, such as anticoagulant, to cause a controlled amount of beneficial agent to enter the passing blood in a manner that is substantially uniform over time. The beneficial agent is typically in dry form until it enters into contact with the blood. Accordingly, no substantial portion of the blood is exposed to a significantly higher concentration of the beneficial agent than other portions of the blood.